A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Abatacept (Primary)
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Acronyms ABAGART
- 20 Aug 2024 Status changed from active, no longer recruiting to recruiting.
- 12 Oct 2022 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 12 Oct 2022 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2026.